Manning Meredith
Chief Commercial Officer
Manning Meredith has filed 4 SEC Form 4 filings (6 transaction rows) across 1 company, with disclosures dating back to 2025. 4 of those filings fall inside the rolling window. Most recent filing: May 18, 2026.
On the most recent filing, Manning Meredith is listed as Chief Commercial Officer at SOLENO THERAPEUTICS INC. Inside the rolling window, Manning Meredith reported no open-market purchases and 1 open-market sale totaling $229K in SLNO.
Companies traded
Other insiders at SLNO
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$229K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Manning Meredith made?
Manning Meredith has filed 4 SEC Form 4 filings (6 transaction rows) across 1 company since 2025.
Which companies does Manning Meredith trade?
Manning Meredith has filed SEC Form 4 disclosures for 1 company, including SLNO.
When was Manning Meredith's most recent SEC Form 4 filing?
Manning Meredith's most recent SEC Form 4 filing on Tracefour is dated May 18, 2026.
What is Manning Meredith's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Manning Meredith is listed as Chief Commercial Officer.
What is Manning Meredith's total buy and sell value in the current window?
Inside the rolling retention window, Manning Meredith bought $0 and sold $229K based on SEC Form 4 filings.
What was Manning Meredith's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 7,522 SLNO shares on 2026-03-27, worth $229K, per SEC Form 4 filings.